Suchergebnisse - "малигнизация"

  1. 1
  2. 2

    Quelle: SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; Vol. 4 No. 3 (2025): SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; 215-219 ; НАУЧНЫЙ ЖУРНАЛ ПРИКЛАДНЫХ И МЕДИЦИНСКИХ НАУК; Том 4 № 3 (2025): SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; 215-219 ; 2181-3469

    Dateibeschreibung: application/pdf

  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    Quelle: PULMONOLOGIYA; Том 32, № 2 (2022); 261-269 ; Пульмонология; Том 32, № 2 (2022); 261-269 ; 2541-9617 ; 0869-0189

    Dateibeschreibung: application/pdf

    Relation: https://journal.pulmonology.ru/pulm/article/view/3864/3211; Gélinas J.F., Manoukian J., Côté A. Lung involvement in juvenile onset recurrent respiratory papillomatosis: a systematic review of the literature. Int. J. Pediatr. Otorhinolaryngol. 2008; 72. (4): 433–452. DOI:10.1016/j.ijporl.2007.12.003; Lindeberg H., Oster S., Oxlund I., Elbrønd O. Laryngeal papillomas: classification and course. Clin. Otolaryngol. Allied Sci. 1986; 11 (6): 423–429. DOI:10.1111/j.1365-2273.1986.tb02032.x.; Doyle D.J., Gianoli G.J., Espinola T., Miller R.H. Recurrent respiratory papillomatosis: juvenile versus adult forms. Laryngoscope. 1994; 104 (5, Pt 1). 523–527. DOI:10.1002/lary.5541040503.; Солдатский Ю.Л. Рецидивирующий респираторный папилломатоз. Вопросы современной педиатрии. 2007; 6 (1): 69–74.; Derkay C.S., Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope. 2008; 118 (7): 1236–1247. DOI:10.1097/mlg.0b013e31816a7135.; Soldatski I.L. et al. Tracheal, bronchial, and pulmonary papillomatosis in children. Laryngoscope. 2005; 115 (10): 1848–1854. DOI:10.1097/01.mlg.0000173155.57491.2a.; Zawadzka-Głos L., Jakubowska A., Chmielik M. et al. Lower airway papillomatosis in children. Int. J. Pediatr. Otorhinolaryngol. 2003; 67 (10): 1117–1121. DOI:10.1016/S0165-5876(03)00191-5.; Рябова М. А., Молодцова В. П., Улупов М. Ю. и др. Рентгенобронхологические методы диагностики и лечения рецидивирующего папилломатоза верхних и нижних дыхательных путей у взрослых. Лучевая диагностика и терапия. 2015; 6 (3): 44–52. DOI:10.22328/2079-5343-2015-3-44-52.; Carifi M., Napolitano D., Morandi M., Dall’Olio D. Recurrent respiratory papillomatosis: current and future perspectives. Ther. Clin. Risk Manag. 2015; 11: 731–738. DOI:10.2147/TCRM.S81825.; Moldan M.M., Bostrom B.C., Tibesar R.J. et al. Epidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis. F1000Res. 2013; 2: 202. DOI:10.12688/f1000research.2-202.v1.; Shah U., Lall A., Kumar J. Treatment option in recurrent respiratory papillomatosis (RRP) needing frequent deobstruction. Eur. Respir. J. 2016; 48 (Suppl. 60): PA765. DOI:10.1183/13993003.congress-2016.PA765; Best S. R., Friedman A. D., Landau-Zemer T. et al. Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis. Ann. Otol. Rhinol. Laryngol. 2012; 121 (9): 587–593. DOI:10.1177/000348941212100905.; Sidell D.R., Nassar M., Cotton R.T. et al. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann. Otol. Rhinol. Laryngol. 2014; 123 (3): 214–221. DOI:10.1177/0003489414522977.; Rogers D. J., Ojha S., Maurer R., Hartnick C. J. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol. Head Neck Surg. 2013; 139 (5): 496–501. DOI:10.1001/jamaoto.2013.1810.; Рябова М.А., Молодцова В.П., Портнов Г.В. и др. Лечебная тактика у больных с распространением респираторного папилломатоза на легкие. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2014; 20 (4): 52–62.; Molodtsova V., Ryabova M., Dvorakovskaya I. et al. Recurrent respiratory papillomatosis with lung involvement. Respir. Med. Case Rep. 2019; 25: 323–326. DOI:10.1016/j.rmcr.2018.10.019.; Молодцова В.П., Акопов А.Л., Двораковская И.В. и др. Современные бронхологические методы диагностики и лечения рецидивирующего папилломатоза трахеи, бронхов и легких взрослых. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2018; 24 (3): 40–54.; https://journal.pulmonology.ru/pulm/article/view/3864

  9. 9

    Quelle: Head and Neck Tumors (HNT); Том 12, № 1 (2022); 79-85 ; Опухоли головы и шеи; Том 12, № 1 (2022); 79-85 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2022-12-1

    Dateibeschreibung: application/pdf

    Relation: https://ogsh.abvpress.ru/jour/article/view/739/517; Bouckaert M., Munzhelele T.I., Feller L. et al. The clinical characteristics of oral squamous cell carcinoma in patients attending the Medunsa Oral Health Centre, South Africa. Integr Cancer Sci Therap 2016;3:575–8. DOI:10.15761/ICST.1000207.; Borse V., Konwar A.N., Buragohain P. Oral cancer diagnosis and perspectives in India. Sens Int 2020;1:100046. DOI:10.1016/j.sintl.2020.100046.; Bugshan A., Farooq I. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Research 2020;9:229. DOI:10.12688/f1000research.22941.1.; Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2019. 250 с.; Chhabra N., Chhabra S., Sapra N. Diagnostic modalities for squamous cell carcinoma: an extensive review of literature considering toluidine blue as a useful adjunct. J Maxillofac Oral Surg 2015;14(2):188–200. DOI:10.1007/s12663-014-0660-6.; Dhanuthai K., Rojanawatsirivej S., Thosaporn W. et al. Oral cancer: A multicenter study. Med Oral Patol Oral Cir Bucal 2018;23(1):e23–9. DOI:10.4317/medoral.21999.; Shimizu S., Miyazaki A., Sonoda T. et al. Tumor budding is an independent prognostic marker in early stage oral squamous cell carcinoma: With special reference to the mode of invasion and worst pattern of invasion. PLoS One 2018;13(4):0195451. DOI:10.1371/journal.pone.0195451.; Aggarwal N., Bhateja S. Leukoplakia – potentially malignant disorder of oral cavity: A review. Biomed J Sci and Tech Res 2018;4(5):4219–26. DOI:10.26717/BJSTR.2018.04.001126.; Ranganathan K., Kavitha L. Oral epithelial dysplasia: Classifications and clinical relevance in risk assessment of oral potentially malignant disorders. J Oral Maxillofac Pathol 2019;23(1):19–27. DOI:10.4103/jomfp.JOMFP_13_19.; Shirani S., Kargahi N., Razavi S.M., Homayoni S. Epithelial dysplasia in oral cavity Iran J Med Sci 2014;39(5):406–17.; Gupta S., Gupta S. Role of human papillomavirus in oral squamous cell carcinoma and oral potentially malignant disorders: A review of the literature. Indian J Dent 2015;6(2):91–8. DOI:10.4103/0975-962X.155877.; https://ogsh.abvpress.ru/jour/article/view/739

  10. 10

    Quelle: Clinical anatomy and operative surgery; Vol. 20 No. 1 (2021); 35-38
    Клиническая анатомия и оперативная хирургия; Том 20 № 1 (2021); 35-38
    Клінічна анатомія та оперативна хірургія; Том 20 № 1 (2021); 35-38

    Dateibeschreibung: application/pdf

  11. 11

    Quelle: Actual Problems of Pediatrics, Obstetrics and Gynecology; No. 2 (2020); 197-202 ; Актуальные вопросы педиатрии, акушерства и гинекологии; № 2 (2020); 197-202 ; Актуальні питання педіатрії, акушерства та гінекології; № 2 (2020); 197-202 ; 2415-301X ; 2411-4944 ; 10.11603/24116-4944.2020.2

    Dateibeschreibung: application/pdf

  12. 12

    Quelle: Medical Visualization; № 4 (2019); 76-85 ; Медицинская визуализация; № 4 (2019); 76-85 ; 2408-9516 ; 1607-0763

    Dateibeschreibung: application/pdf

    Relation: https://medvis.vidar.ru/jour/article/view/840/577; Nault J.C., Bioulac-Sage P., Zucman-Rossi J. Hepatocellular benign tumours – from molecular classification to personalized clinical care. Gastroenterology. 2013;144: 888–902. https://doi.org/10.1053/j.gastro.2013.02.032; Baum J.K., Bookstein J.J., Holtz F., Klein E.W. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973; 302: 926–929. https://doi.org/10.1016/s0140-6736(73)92594-4; Calderaro J., Labrune P., MorcretteG., RebouissouS., FrancoD., Prévot S., Quaglia A., Bedossa P., Libbrecht L., Terracciano,L., Smit G.P., Bioulac-Sage P., Zucman- Rossi J. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J. Hepatol. 2013; 58: 350–357. https://doi.org/10.1016/j.jhep.2012.09.030; Bonder A., Afdhal N. Evaluation of liver lesions. Clin. Liver Dis. 2012; 16: 271–283. https://doi.org/10.1016/j.cld.2012.03.001; Rooks J.B., Ory H.W., Ishak K.G., Strauss L.T., Greenspan J.R., Hill A.P., Tyler C.W. Jr. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA. 1979; 242 (7): 644–648.; Bioulac-Sage P., Laumonier H., Couchy G., Le Bail B., Sa Cunha A., Rullier A., Laurent C., Blanc J.F., Cubel G., Trillaud H., Zucman-Rossi J., Balabaud C., Saric J. Hepatocellular Adenoma Management and Phenotypic Classification: the Bordeaux Experience. Hepatology. 2009; 50 (2): 481–489. https://doi.org/10.1002/hep.22995; EASL CPG benignlivertumours. J. Hepatol. 2016; 65: 386–398. https://doi.org/10.1016/j.jhep.2016.04.001; Choi W-T., Kakar S. Atypical Hepatocellular Neoplasms: Review of Clinical, Morphologic, Immunohistochemical, Molecular, and Cytogenetic Features. Adv. Anat. Pathol. 2018; 25 (4): 254–262. https://doi.org/10.1097/PAP.0000000000000189; Sempoux C., Balabaud C., Bioulac-Sage P. Malignant transformation of hepatocellular adenoma. Hepatic Oncol. 2014; 1: 421–431. https://doi.org/10.2217/hep.14.14; Rebouissou S., Franconi A., Calderaro J., Letouzé E., Imbeaud S., Pilati C., Nault J.C., Couchy G., Laurent A., Balabaud C., Bioulac-Sage P., Zucman-Rossi J. Genotype phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression. Hepatology. 2016; 64 (6): 2047–2061. https://doi.org/10.1002/hep.28638; Brant W.E. Brant and Helms’ Fundamentals of Diagnostic Radiology 5ed. Wolters Kluwer; 2007; 2231 p.; Braga L., Altun E., Armao D., Semelka RC. Abdominalpelvic MRI. 4ed. Wiley-Blackwell; 2016; Chapter 2, 90: 92–93.; Harisinghani M.G., Mueller P.R. Teaching Atlas of Abdominal Imaging. Thieme. 2009; 11,12 p.; Laumonier H., Bioulac-Sage P., Laurent C., Zucman- Rossi J., Balabaud C., Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology. 2008; 48: 808–818. https://doi.org/10.1002/hep.22417; van Aalten S.M., Thomeer M.G., Terkivatan T., Dwarkasing R.S., Verheij J., de Man R.A., Ijzermans J.N. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology. 2011; 261: 172–181. https://doi.org/10.1148/radiol.11110023; Лукьянченко А.Б., Медведева Б.М. Современные возможности лучевой диагностики гепатоцеллюлярных аденом (обзор литературы и собственные наблюдения). Медицинская визуализация. 2013; 1, 33–43.; Dharmana H., Saravana-Bawan S., Girgis S., Low G. Hepatocellular adenoma: imaging review of the various molecular subtypes. Clin. Radiol. 2017; 72: 276–285. https://doi.org/10.1016/j.crad.2016.12.020; Reizine E., Ronot M., Pigneur F., Purcell Y., Mulé S., Dioguardi Burgio M., Calderaro J., Amaddeo G., Laurent A., Vilgrain V., Luciani A. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping. Eur. Radiol. 2019; 29 (7): 3791–3801. https://doi.org/10.1007/s00330-019-06150-7; Sciarra A., Schmidt S., Pellegrinelli A., Maggioni M., Dondossola D., Pasquier J., Cigala C., Tosi D., Halkic N., Bulfamante G., Viale G., Bosari S., Balabaud C., Bioulac- Sage P., Sempoux C. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. Liver Int. 2019; 39 (1): 158–167. https://doi.org/10.1111/liv.13964; Guo Y., Li W., Xie Z., Zhang Y., Fang Y., Cai W., Hong G. Diagnostic Value of Gd-EOB-DTPA-MRI for Hepatocellular Adenoma: A Meta-Analysis. J. Cancer. 2017; 8 (7): 1301–1310. https://doi.org/10.7150/jca.17778; https://medvis.vidar.ru/jour/article/view/840

  13. 13

    Quelle: Creative surgery and oncology; Том 9, № 2 (2019); 144-150 ; Креативная хирургия и онкология; Том 9, № 2 (2019); 144-150 ; 2076-3093 ; 2307-0501 ; 10.24060/2076-3093-2019-9-2

    Dateibeschreibung: application/pdf

    Relation: https://www.surgonco.ru/jour/article/view/388/346; Hartge P., Hayes R., Reding D., Sherman M.E., Prorok P., Schiffman M., et al. Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial. Am J Obstet Gynecol. 2000;183(5):1232–37. PMID: 11084571; Dorum A., Blom G.P., Ekerhovd E., Granberg S. Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study. Am J Obstet Gynecol. 2005;192(1):48–54. DOI:10.1016/j. ajog.2004.07.038; Greenlee R.T., Kessel B., Williams C.R., Riley T.L., Ragard L.R., Hartge P., et al. Prevalence, incidence, and natural history of simple ovarian cysts among women >55 years old in a large cancer screening trial. Am J Obstet Gynecol. 2010;202(4):373, e1–9. DOI:10.1016/j. ajog.2009.11.029; Zalud I., Busse R., Kurjak B.F. Asymptomatic simple ovarian cyst in postmenopausal women: syndrome of ‘visible ovary’. Donald School J Ultrasound Obstet Gynecol. 2013;7(2):182–86. DOI:10.5005/jpjournals-10009-1282; Healy D.L., Bell R., Robertson D.M., Jobling T., Oehler M.K., Edwards A., et al. Ovarian status in healthy postmenopausal women. Menopause. 2008;15(6):1109–14. DOI:10.1097/ gme.0b013e31816ddb6f; Кузнецова И.В. Аномальные маточные кровотечения у женщин в перименопаузе. М.: ГЭОТАР-Медиа; 2016. Режим доступа: http://www.rosmedlib.ru/book/07-MOD-1993.html; Аксель Е.М. Статистика злокачественных новообразований женской половой сферы. Онкогинекология. 2012;(1):18–23.; Хохлова С.В., Давыдова И.Ю., Новикова Е.Г., Телетаева Г.М., Трякин А.А., Урманчеева А.Ф. Практические рекомендации по лекарственному лечению неэпителиальных опухолей яичников. В кн. Практические рекомендации RUSSCO 2016. М.; 2016. С. 135–46. DOI:10.18027/2224-5057-2016-4s2-135-146; Тюляндин С.А., Деньгина Н.В., Коломиец Л.А., Морхов К.Ю., Нечушкина В.М., Покатаев И.А. и др. Практические рекомендации по лекарственному лечению рака яичников / первичного рака брюшины / рака маточных труб. В кн. Практические рекомендации RUSSCO 2017. М.; 2017. С. 135–45. DOI:10.18027 / 2224-5057- 2017-7-3s2-135-145; Guraslan H., Dogan K. Management of unilocular or multilocular cysts more than 5 centimeters in postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2016;203:40–3. DOI:10.1016/j.ejogrb.2016.05.028; Alcazar J.L., Pascual M.A., Marquez R., Ajossa S., Juez L., Graupera B., et al. Malignancy risk of sonographically benign appearing purely solid adnexal masses in asymptomatic postmenopausal women. Menopause. 2017;24(6):613–16. DOI:10.1097/GME.0000000000000814; Sarkar M., Wolf M.G. Simple ovarian cysts in postmenopausal women: scope of conservative management. Eur J Obstet Gynecol Reprod Biol. 2012;162(1):75–8. DOI:10.1016/j.ejogrb.2011.12.034; Valentin L., Ameye L., Franchi D., Guerriero S., Jurkovic D., Savelli L., et al. Risk of malignancy in unilocular cysts: a study of 1148 adnexal masses classified as unilocular cysts at transvaginal ultrasound and review of the literature. Ultrasound Obstet Gynecol. 2013;41(1):80–9. DOI:10.1002/uog.12308; Froyman W., Landolfo C., De Cock B., Wynants L., Sladkevicius P., Testa A.C., et al. Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. Lancet Oncol. 2019;20(3):448–58. DOI:10.1016/S1470-2045(18)30837-4; The management of ovarian cysts in postmenopausal women: Greentop Guideline No. 34 [Internet]. London; RCOG: 2016. Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/greentop-guidelines/gtg_34.pdf; Parker W.H. Bilateral oophorectomy: Solving the risk/benefit equation — Choosing candidates, monitoring outcomes Prophylactic bilateral oophorectomy at the time of hysterectomy confers long-term benefits for many women. Contemporary OB/GYN. 2011 July;56:[about 2 p.]. Available from: https://www.contemporaryobgyn.net/modernmedicine-now/bilateral-oophorectomy-solving-riskbenefit-equation-- choosing-candidates-monitoring-outcomes; Tellawi R.A., Morozov V.V. Prophylactic salpingectomy: The future of ovarian cancer prevention. Contemporary OB/GYN. 2014 March;59:[about 3 p.]. Available from: https://www. contemporaryobgyn.net/gynecology/prophylactic-salpingectomyfuture-ovarian-cancer-prevention; Committee Opinion No.620: Salpingectomy for ovarian cancer prevention. Obstet Gynecol. 2015;125:279–81. DOI:10.1097/01. AOG.0000459871.88564.09; Foulkes W.D. Preventing ovarian cancer by salpingectomy. Curr Oncol. 2013; 20(3):139–42. DOI:10.3747/co.20.1613; Hanley G.E., McAlpine J.N., Kwon J.S., Mitchell G. Opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol Res Pract. 2015;2:5. DOI:10.1186/s40661-015-0014-1; Hickey M., Ambekar M., Hammond I. Should the ovaries be removed or retained at the time of hysterectomy for benign disease? Hum Reprod Update. 2010;16(2):13141. DOI:10.1093/humupd/dmp037; Shuster L.T., Grossardt B.R., Gostout B.S., Rocca W.A. Prophylactic bilateral oophorectomy jeopardizes long-term health. Sex Reprod Menopause. 2010;8(4):51–8.; McCarthy A.M., Menke A., Ouyang P., Visvanathan K. Bilateral oophorectomy, body mass index, and mortality in U.S. women aged 40 years and older. Cancer Prev Res. 2012;5(6):847–54. DOI:10.1158/19406207; Shu C.A., Pike M.C., Jotwani A.R., Friebel T.M., Soslow R.A., Levine D.A., et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016;2(11):1434–40. DOI:10.1001/jamaoncol.2016.1820; https://www.surgonco.ru/jour/article/view/388

  14. 14

    Quelle: Medical Visualization; № 2 (2018); 84-93 ; Медицинская визуализация; № 2 (2018); 84-93 ; 2408-9516 ; 1607-0763

    Dateibeschreibung: application/pdf

    Relation: https://medvis.vidar.ru/jour/article/view/550/470; Сурков А.Н., Намазова-Баранова Л.С., Потапов А.С., Савостьянов К.В., Пушков А.А., Никитин А.Г., Полякова С.И., Рязанов М.В., Кустова О.В., Барский В.И., Степанян М.Ю. Случай множественных аденом печени у подростка с тяжелым течением гликогеновой болезни типа Ib. Вестник РАМН. 2014; 11–12: 54–59.; Vijay A., Elaffandi A., Khalaf H. Hepatocellular adenoma: An update. Wld J. Hepatol. 2015; 7 (25): 2603.; Mamada Y., Onda M., Tajiri T., Akimaru K., Yoshida H., Taniai N., Mineta S., Hirakata A., Hirose Y. Liver cell adenoma in a 26-year-old man. J. Nippon Med. School. 2001; 68 (6): 516–519.; Herman P., Pugliese V., Machado M. A., Montagnini A. L., Salem M. Z., Bacchella T., D’Albuquerque L. A., Saad W.A., Machado M. C., Pinotti H. W. Hepatic adenoma and focal nodular hyperplasia: differential diagnosis and treatment. Wld J. Surg. 2000; 24 (3): 372–376.; Toso C., Majno P., Andres A., Rubbia-Brandt L., Berney T., Buhler L., Morel P., Mentha G. Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors. Wld J. Gastroenterol. 2005; 11 (36): 56–91.; Dokmak S., Paradis V., Vilgrain V., Sauvanet A., Farges O., Valla D., Bedossa P., Belghiti J. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009; 137 (5): 1698–1705. DOI:10.1053/j.gastro.2009.07.061.; Stoot J.H., Coelen R.J., De Jong M.C., Dejong C.H. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB. 2010; 12 (8): 509–522. DOI:10.1111/j.1477-2574.2010.00222.x.; Farges O., Ferreira N., Dokmak S., Belghiti J., Bedossa P., Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. Gut. 2011; 60 (1): 85–89. DOI:10.1136/gut.2010.222109.; Zucman Rossi J., Jeannot E., Van Nhieu J. T., Scoazec J. Y., Guettier C., Rebouissou S., Bacq Y., Leteurtre E., Paradis V., Michalak S., Wendum D., Chiche L., Fabre M., Mellottee L., Laurent C., Partensky C., Castaing D., Zafrani E.S., Laurent-Puig P., Balabaud C., Bioulac-Sage P. Genotype–phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006; 43 (3): 515–524. DOI:10.1002/hep.21068.; Lade A.G., Monga S.P. Beta-catenin signaling in hepatic development and progenitors: Which way does the WNT blow? Developmental Dynamics. 2011; 240 (3): 486–500. DOI:10.1002/dvdy.22522.; Bioulac-Sage P., Balabaud C., Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Digest. Surg. 2010; 27 (1): 39–45. DOI:10.1159/000268406.; Toiyama Y., Inoue Y., Yasuda H., Yoshiyama S., Araki T., Miki C., Kusunoki M. Hepatocellular adenoma containing hepatocellular carcinoma in a male patient with familial adenomatous polyposis coli: Report of a case. Surg. Today. 2011; 41 (10): 1442. DOI:10.1007/s00595-010-4451-5.; Nault J.C., Bioulac-Sage P., Zucman-Rossi J. Hepatocellular benign tumors – from molecular classification to personalized clinical care. Gastroenterology. 2013; 144 (5): 888–902. DOI:10.1053/j.gastro.2013.02.032.; Bioulac Sage P., Laumonier H., Couchy G., Le Bail B., Sa Cunha A., Rullier A., Laurent C., Blanc J.F., Cubel G., Trillaud H., Zucman Rossi J., Balabaud C., Saric J. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009; 50 (2): 481–489. DOI:10.1002/hep.22995.; Bioulac-Sage P., Sempoux C., Balabaud C. Hepatocellular adenoma: classification, variants and clinical relevance. Seminars in Diagn. Pathol. 2017; 34 (20): 112–125. DOI:10.1053/j.semdp.2016.12.007.; Ronald M., Woodfield J., McCall J., Koea J. Hepatic adenomas in male patients. HPB. 2004; 6 (1): 25–27. DOI:10.1080/13651820310020846.; Vázquez J.J., Marigil M.A. Liver-cell adenoma in an epileptic man on barbiturates. Histol. Histopathol. 1989; 4 (3): 301–303.; Tazawa K., Yasuda M., Ohtani Y., Makuuchi H., Osamura R.Y. Multiple hepatocellular adenomas associated with long-term carbamazepine. Histopathology. 1999; 35 (1): 92–94. DOI:10.1046/j.1365-2559.1999.0728g.x.; Ferko A., Bedrna J., Nozicka J. Pigmented hepatoc ellular adenoma of the liver caused by long-term use of phenobarbital. Rozhl chir. 2003; 82 (4): 192–195.; Seki A., Inoue T., Maegaki Y., Sugiura C., Toyoshima M., Akaboshi S., Ohno K. Polycystic ovary syndrome and hepatocellular adenoma related to long-term use of sodium valproate in a young woman. No to hattatsu. 2006; 38 (3): 205–208.; Lautz T.B., Finegold M.J., Chin A.C., Superina R.A. Giant hepatic adenoma with atypical features in a patient on oxcarbazepine therapy. J. Pediatr. Surg. 2008; 43 (4): 751–754. DOI:10.1016/j.jpedsurg.2007.11.036.; Lee P.U., Roberts L.R., Kaiya J.K., Lee C.U. Hepatic adenomas associated with anti-epileptic drugs: a case series and imaging review. Abdom. Imaging. 2010; 35 (2): 208–211.; Bioulac-Sage P., Sempoux C., Possenti L., Frulio N., Laumonier H., Laurent C., Chiche L., Blanc J. F., Saric J., Trillaud H., Le Bail B., Balabaud C. Pathological diagnosis of hepatocellular cellular adenoma according to the clinical context. Int. J. Hepatol. 2013; 2013: 253261. DOI:10.1155/2013/253261.; Davis M., Portmann B., Searle M., Wright R., Williams R. Histological evidence of carcinoma in a hepatic tumour associated with oral contraceptives. Br. Med J. 1975; 4 (5995): 496–498.; Deneve J. L., Pawlik T. M., Cunningham S., Clary B., Reddy S., Scoggins C. R., Martin C.G. Angelica M., Staley C.A., Choti M.A., Jarnagin, W. R., Schulick R.D. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann. Surg. Oncol. 2009; 16 (3): 640–648. DOI:10.1245/s10434-008-0275-6.; Farges O., Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature. Digest. Surg. 2010; 27 (1): 32–38. DOI:10.1159/000268405.; An S. L., Wang L. M., Rong W. Q., Wu F., Sun W., Yu, W. B., Feng L., Liu F.Q., Tian F., Wu J. X. Hepatocellular adenoma with malignant transformation in male patients with non-cirrhotic livers. Chinese J. Cancer. 2015; 34 (3): 17. DOI:10.1186/s40880-015-0014-x.; Micchelli S.T., Vivekanandan P., Boitnott J.K., Pawlik T.M., Choti M.A., Torbenson M. Malignant transformation of hepatic adenomas. Modern Pathol. 2008; 21 (4): 491. DOI:10.1038/modpathol.2008.8.; Laumonier H., Bioulac-Sage P., Laurent C., ZucmanRossi J., Balabaud C., Trillaud H. Hepatocellular aden omas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology. 2008; 48 (3): 808–818. DOI:10.1002/hep.22417.; van Aalten S.M., Thomeer M.G., Terkivatan T., Dwarkasing R.S., Verheij J., de Man R., Ijzermans J.N. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology. 2011; 261 (1): 172–181. DOI:10.1148/radiol.11110023.; Ronot M., Bahrami S., Calderaro J., Valla D.C., Bedossa P., Belghti J., Vilgrain V., Paradis, V. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology. 2011; 53 (4): 1182–1191. DOI:10.1002/hep.24147.; Лукьянченко А.Б., Медведева Б.М. Современные возможности лучевой диагностики гепатоцеллюлярных аденом (обзор литературы и собственные наблюдения). Медицинская визуализация. 2013; (1): 33–43.; Yoneda N., Matsui O., Kitao A., Kozaka K., Kobayashi S., Sasaki M. Yoshida K., Inoue D., Minami T., Gabata, T. Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background. Radiographics. 2016; 36 (7): 2010–2027. DOI:10.1148/rg.2016160037.; Agarwal S., Fuentes-Orrego J. M., Arnason T., Misdraji J., Jhaveri K.S., Harisinghani M., Hahn P. F. Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid–enhanced MRI. Am. J. Roentgenol. 2014; 203 (4): 408–414. DOI:10.2214/AJR.13.12251.; Fukusato T., Soejima Y., Kondo F., Inoue M., Watanabe M., Takahashi Y., Aso T., Uozaki H., Sano K., Sanada Y., Niki T. Preserved or enhanced OATP1B3 expression in hepatocellular adenoma subtypes with nuclear accumulation of β-catenin. Hepatol. Res. 2015; 45 (10). DOI:10.1111/hepr.12453.; Kwok W.Y., Hagiwara S., Nishida N., Watanabe T., Sakurai T., Ida H., Minami Y.,Takita M., Minami T., Iwanishi M., Chishina H., Kono M., Ueshima K., Komeda Y., Arizumi T., Enoki E., Nakai T., Kumabe T., Nakashima O., Kondo F., Kudo M. Malignant transformation of hepatocellular adenoma. Oncology. 2017; 92(1): 16–28. DOI:10.1159/000451012.; Agnello F., Ronot M., Valla D.C., Sinkus R., Van Beers B.E., Vilgrain V. High-b-value diffusion-weighted MR imaging of benign hepatocellular lesions: quantitative and qualitative analysis. Radiology. 2012; 262 (2): 511–519. DOI:10.1148/radiol.11110922.; Lee S.A., Lee .H., Jung W.Y., Lee ., Choi J.W., Kim K.A, Park C.M. Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOBDTPA enhanced MRI: initial experience. Magn. Reson. Imaging. 2011; 29(1): 83–90. DOI:10.1016/j.mri.2010.07.019.; Descottes B., Glineur D., Lachachi F., Valleix D., Paineau J., Hamy A., Morino M., Bismuth H., Castaing D., Savier E., Honore P., Detry O., Legrand M., Azagra J.S., Goergen M., Ceuterick M., Marescaux J., Mutter D., Hemptinne B., Troisi R., Weerts J., Dallemagne B., Jehaes C., Gelin M., Donckier V., Aerts R., Topal B., Bertrand C., Mansvelt B., Van Krunckelsven L., Herman D., Kint M., Totte E., Schockmel R., GigoT J.F. Laparoscopic liver resection of benign liver tumors. Surg. Endosc. Intervent. Techn. 2003; 17 (1): 23–30. DOI:10.1007/s00464-002-9047-8.; Khanna M., Ramanathan S., Fasih N., Schieda N., Virmani V., McInnes M.D. Current updates on the molecular genetics and magnetic resonance imaging of focal nodular hyperplasia and hepatocellular adenoma. Insights into imaging. 2015; 6 (3): 347–362. DOI:10.1007/s13244-015-0399-8.; https://medvis.vidar.ru/jour/article/view/550

  15. 15

    Quelle: Head and Neck Tumors (HNT); Том 7, № 2 (2017); 81-91 ; Опухоли головы и шеи; Том 7, № 2 (2017); 81-91 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2017-7-2

    Dateibeschreibung: application/pdf

    Relation: https://ogsh.abvpress.ru/jour/article/view/269/274; Шелковникова А.В. , Осипов В.Д., Герасимова И.Ю. Неспецифические опухолевые маркеры и клинико-морфологические показатели в диагностике и лечении предрака и раннего рака гортани. Вестник оториноларингологии 2008;5(прил.):307–8.; Alkotyfan K., Wiegand S., Müller H.H. et al. Cyfra 21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharynx. Anticancer Res 2010;30(6):2291–6. PMID: 20651382.; Céruse P., Rabilloud M., Charrié A. et al. Study of Сyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol 2005;114(10):768–76. DOI:10.1177/000348940511401006. PMID: 16285267.; Eleftheriadou A., Chalastras T., Ferekidou E. et al. Clinical effectiveness of tumor markers in squamous cell carcinoma of the larynx. Anticancer Res 2006;26(3B):2493–7. PMID: 16821638.; Титов В.Н., Крылин В.В. Стресс. Белки-шапероны. Нарушение биологической функции эндоэкологии и биологических реакций экскреции, воспаления и артериального давления (лекция). Клиническая лабораторная диагностика 2010;5:20–35.; Chen J.H., Chen L.M., Xu L.Y. et al. Expression and significance of heat shock proteins in esophagal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi 2006;28(10):758-61. [Article in Chinese] PMID: 17366788.; Ciocca D., Calderwood S.K. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10(2):86–103. PMID: 6038406.; Blackwell K.E., Fu Y.S., Calcaterra T.C. et al. Laryngeal dysplasia. A clinicopathologic study. Cancer 1995;75(2):457–63. PMID: 7812916.; Cupić H., Kruslin B., Belicza M. Epithelial hyperplastic lesions of the larynx in biopsy specimens. Acta Otolaryngol Suppl. 1997;527:103–4 PMID: 9197494.; Киселев В.И., Северин Е.С., Пальцев М.А. Противоопухолевые вакцины. Белки теплового шока как индукторы противоопухолевого иммунитета. Молекулярная медицина 2005;1:3–21.; https://ogsh.abvpress.ru/jour/article/view/269

  16. 16
  17. 17
  18. 18

    Quelle: Wounds and wound infections. The prof. B.M. Kostyuchenok journal; Том 3, № 1 (2016); 52-56 ; Раны и раневые инфекции. Журнал имени проф. Б.М. Костючёнка; Том 3, № 1 (2016); 52-56 ; 2500-0594 ; 2408-9613 ; 10.17650/2408-9613-2016-3-1

    Dateibeschreibung: application/pdf

    Relation: https://www.riri.su/jour/article/view/80/85; Marjolin J.N. Ulcere: dictionneraire de medicine. Paris: Bechet, 1828.; Ozek C., Celik N., Bilkay U. et al. Marjolin’s ulcer of the scalp; report of 5 cases and review of the literature. J Burn Care Rehabil 2001;22(1):65–9. PMID: 11227688.; Sabin S.R., Goldstein G., Rosenthal H.G., Haynes K.K. Aggressive squamous cell carcinoma originating as a Marjolin’s ulcer. Dermatol Surg 2004;30(2 Pt 1):229–30. PMID: 14756658.; Schmidt I., Friedel R., Schnitz H. The Marjolin’s ulcer; a malignant and rare complication after burn trauma of the upper extremely – a case report. Unfallchirurg 1999;103: 923–4.; Garzon R., Burgos E.B., Garzon F.L. et al. Marjolin ulcer. Rev Fac Cien Med Univ Nac Cordoba 2001;58(1):93–7. PMID: 12934265.; Smith J., Mello L.F., Nogueira Neto N.C. et al. Malignancy in chronic ulcers and scars of the leg (Marjolin’s ulcer): a study of 21 patients. Skeletal Radiol 2001;30(6): 331–7. PMID: 11465774.; Trent J.T., Kirsner R.S. Wounds and malignancy. Adv Skin Wound Care 2003;16(1):31–4. PMID: 12582304.; Koval-Vern A., Criswell B.K. Burn scar neoplasm: a literature review and statistical analysis. Burns 2005;31(4):403–13. DOI:10.1016/j.burns.2005.02.015. PMID: 15896501.; Ибрагимов Н.А. Рак кожи на рубцах. Автореф. дисс. … канд. мед. наук. Ташкент, 1987. 25 с. [Ibragimov N.А. Cancer skin on cicatrix. Author’s abstract of thesis . of candidate of medicine. Таshkent, 1987. 25 p. (In Russ.)].; Wong A., Johns M.M., Teknos T.N. Marjolin’s ulcer arising in a previously grafted burn of the scalp. Otolaryngol Head Neck Surg 2003;128(6):915–6. PMID: 12825051.; Copcu E., Aktas A., Sisman N., Oztan Y. Thirty-one cases of Marjolin’s ulcer. Clin Exp Dermatol 2003;28(2):138–141. PMID: 12653697.; Blidi M., Gatefosse M., Barjonnet G. Epidermoid carcinoma complicating chronic osteomyelitis of the femur. Rev Rhum Engl Ed 1996;63(1):62–4. PMID: 9064114.; Bowers R.F., Young J.M. Carcinoma arising in scars, osteomyelitis, and fistulae. Arch Surg 1960;80:564–70. PMID: 13803468.; Лыс П.В., Гвоздяк Н.Н., Родионова Н.А. Рак на почве трофических язв и остеомиелитических свищей. Клиническая хирургия 1980;(5):36–9. [Lys P.V., Gvozdyak N.N., Rodionovа N.А. Cancer on the background of trophic ulcers and osteomyelitic fistulas. Klinicheskaya khirurgiya = Clinical Surgery 1980;(5):36–9. (In Russ.)].; Esther R.J., Lamps L., Schwarz H.S. Marjolin ulcers: secondary carcinomas in chronic wounds. J South Orthop Assoc 1999;8(3):181–7. PMID: 12132863.; Kirsner R.S., Spenser J., Falanga V. et al. Squamous cell carcinoma arising in osteomyelitis and chronic wounds. Treatment with Mohs micrographic surgery vs amputation. Dermatol Surg 1996;22(12):1015–8. PMID: 9078313.; Игитханян А.М. Злокачественные пере- рождения хронических остеомиелитических свищей и длительно незаживающих язв. В сб.: Материалы Всесоюзной конференции по лечебно-профилактическому обслуживанию инвалидов Отечественной войны. М., 1966. С. 78–9. [Igitkhanyan А.М. Malignant changes of chronic osteomyelitic fistulas and indolent ulcers. In: Маterials of the All-Union Conference for the Treatment and Prophylactic Servicing of World War II Disabled Veterans. Мoscow, 1966. Pp. 78–9. (In Russ.)].; Adelman H.M., Wallach P.M., Flannery M.T. Ewing’s sarcoma of the ilium presenting as unilateral sacroiliitis. J Rheumatol 1991;18(7):1109–11. PMID: 1833545.; Pouchot J., Barge J., Marchand A. et al. Ewing’s sarcoma of the ilium mimicking an infectious sacroiliitis. J Rheumatol 1992;19(8):1318–20. PMID: 1404177.; Lyall H.A., Constant C.R., Wraight E.P. Case report: Ewing’s sarcoma in distal tibial metaphysis mimicking osteomyelitis. Clin Radiol 1993;48(2):140–2. PMID: 8004895.; Щупак М.Ю. Первичные и метастатические опухоли бедренной кости. В сб.: Материалы Х съезда онкологов Украины. Ялта, 2001. [Shchupak М.Yu. Primary and metastatic femoral tumors. In: Маterials of the Х Conference of Ukrainian Oncologists. Yaltа, 2001. (In Russ.)]; https://www.riri.su/jour/article/view/80

  19. 19
  20. 20